ClinicalTrials.gg
Sign In

Multiple Sclerosis, Relapsing-Remitting clinical trials

The registry lists 618 studies for Multiple Sclerosis, Relapsing-Remitting across more than 10 countries. 82 are recruiting or about to start. 551 of them are mainly about Multiple Sclerosis, Relapsing-Remitting (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

ClinicalTrials.gov finds 745 studies for Multiple Sclerosis, Relapsing-Remitting. How that becomes 616 here

This page counts the studies the registry files under Multiple Sclerosis, Relapsing-Remitting, and those it files under no condition that list Multiple Sclerosis, Relapsing-Remittingthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 745Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1List Multiple Sclerosis, Relapsing-Remitting as a condition, but the registry did not file them under itMost often written as “Relapsing Remitting Multiple Sclerosis RRMS” (1). The registry filed them under other conditions only, most often Multiple Sclerosis (1).
  3. −128Match it another way90 name it in the title, 2 in a keyword, and 36 by a synonym or other text the search reads.
  4. 616The count on this page1 of them list Multiple Sclerosis, Relapsing-Remitting in their own words; the registry filed them under no condition.

Get an email when these change. Save the Multiple Sclerosis, Relapsing-Remitting studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
368
Terminated
67
Recruiting
59
Status unknown
39
Active, not recruiting
36
Withdrawn
23

Phase

Phase 2
120
Phase 3
97
Phase 4
81
Phase 1
59
Early Phase 1
6

Where

United States
229
Germany
106
France
82
Italy
71
Poland
64
Canada
64

Who runs them

Biogen (78) · Novartis Pharmaceuticals (30) · Merck KGaA, Darmstadt, Germany (26) · Bayer (17) · Teva Branded Pharmaceutical Products R&D, Inc. (12) · Hoffmann-La Roche (11) · GlaxoSmithKline (9) · Johns Hopkins University (9)

What is being tested here

Drugs under test in Multiple Sclerosis, Relapsing-Remitting studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Ublituximab304
Ocrelizumab2610
Rituximab257
Cladribine125
Clemastine102
Remibrutinib101
Taurine101
Ifenprodil101
Ozanimod111
Rocbrutinib101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Antihistamines 2 open · Antimetabolites 1 open · Corticosteroids 5 · Statins 5

Coming up

16phase 3 studies under way
31studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 59 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (19%) set no upper age limit and 42 (71%) stop at 75 or younger. 2 (3%) take children under 18. 1 (2%) are for women only and 1 (2%) for men only; 11 (19%) take healthy volunteers.

Recruiting studies that take each age, of 59
AgeWomenMen
101 (2%)1 (2%)
1849 (83%)50 (85%)
3053 (90%)53 (90%)
4056 (95%)56 (95%)
5056 (95%)56 (95%)
6534 (58%)34 (58%)
7521 (36%)21 (36%)
8515 (25%)15 (25%)

Across all 618 studies, recruiting or not: 75% stop at 75 or younger and 70% at 65; 6% take children; 2% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple Sclerosis, Relapsing-Remitting studies take

Of 38 phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo3–41 · 16 studies——
Phase 241 mo22–67 · 25 studies——
Phase 348 mo27–66 · 38 studies38 mo26–65 · 28 studies—
Phase 448 mo22–66 · 28 studies——
Interventional, no phase29 mo15–47 · 81 studies—29 mo15–45 · 79 studies
Observational41 mo23–55 · 67 studies28 mo20–55 · 26 studies48 mo34–56 · 41 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 12, 2026.

Newly registered5

Studies

Recruiting first, then most recently updated. Showing 50 of 618. Browse all 618 → or search them.